Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

AscellaHealth’s Patient-Focused Approach is Best-in-Class Model for Distribution of Rare Disease Therapies

BERWYN, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, distinguishes itself as the partner of choice for rare disease pharmaceutical manufacturers, offering a patient-first, customizable model that supports the successful commercialization and distribution of specialty and rare disease therapies. This commitment is showcased in a three-part series of AscellaHealth Podcast Pulse, featuring Donovan Quill, Chief Strategy Officer, AscellaHealth and Charlie Gayer, Chief Commercial Officer, BioCryst Pharmaceuticals, who highlight the value of these adaptable, patient-focused solutions.

“At AscellaHealth, we recognize that a one-size-fits-all approach doesn’t work when distributing therapies for individuals with complex, chronic and rare diseases,” says Bill Oldham, Chairman and President of AscellaHealth. “That’s why our integrated model delivers the best of all worlds: single-source service, personalized patient support and flexible distribution pathways—ensuring optimal access and outcomes. We’re excited to share this podcast with our colleagues and friends across the industry.”

In part one, the experts explore the critical factors influencing the adoption of exclusive distribution models, including:
•        Product characteristics
•        Patient and prescriber profiles
•        Market dynamics
•        Strategic objectives

Parts two and three focus on the advantages of partnering with a sole-source, exclusive distribution partner and dispel the common misconceptions surrounding this model. A deep dive discussion focuses upon the value of this approach to create more meaningful partnerships, increase stability, and streamline processes for life sciences stakeholders.

“Through exclusive and limited distribution strategies that seamlessly scale into broader, open models, AscellaHealth equips manufacturers with comprehensive, end-to-end solutions that evolve alongside their needs,” states Oldham. “Blending operational efficiency, flexibility and personalized care powered by the human touch, this methodology supports every stage of a product’s lifecycle.”

About AscellaHealth LLC

AscellaHealth is a global partner that delivers proven end-to-end solutions to both life sciences and healthcare companies to enhance the quality of life for patients with complex, chronic conditions. A dedicated team gets critical healthcare products from manufacturers to patients while ensuring an efficient flow of funds between payers and pharma. For more information on our services and solutions, visit www.AscellaHealth.com.

This press release was published by a CLEAR® Verified individual.


Media:

Caroline Chambers
CPR Communications
cchambers@cpronline.com
201.641.1911 x 21

Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.